Evaluation of the effect of Famotidine in esophageal and cardiac cancer

Phase 3

• Conditions: Condition 1: Esopageal Cancer. Condition 2: Cardia Cancer.; Malignant neoplasm of esophagus; Malignant neoplasm of cardia; C16.0

• Registration Number: IRCT20170728035349N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All patients with non-metastatic esophageal cancer and non-metastatic cardiac cancer aged 30 to 75 years who are candidates for radiotherapy and do not receive PPIs and other H2-blocker antagonists.
Aged 30 to 75 years old
Being candidates for chemo radiotherapy
Do not receive PPIs and other H2-blocker antagonists.

Exclusion Criteria

Patients who die during the project.
Patients who are unable to continue treatment due to the severity of treatment complications.
Patients who are unable to continue treatment due to the severity of treatment complications.
Need to use PPI family drugs during the treatment process

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood Complications Chemo Radiotherapy for esophageal and cardiac cancers. Timepoint: Acute blood complications of chemo radiation weekly during radiotherapy with weekly CBC diff check for 5 weeks. Method of measurement: CBC diff blood sample.